Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for HER2-overexpressing breast and gastric cancers.
![FDA Approves New Herceptin Biosimilar for the Treatment of Multiple HER2-Overexpressing Cancers](https://onclive.s3.amazonaws.com/onclive_630x1200.png)
Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for HER2-overexpressing breast and gastric cancers.